STROMECTOL (Ivermectin) is a semisynthetic, anthelmintic agent for oral administration. Ivermectin is derived from the avermectins, a class of highly active broad-spectrum, anti-parasitic agents isolated from the fermentation products of Streptomyces avermitilis.
STROMECTOL is indicated for the treatment of the following infections:
Strongyloidiasis of the intestinal tract. STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis.
This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies.)
Onchocerciasis. STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus.
This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C).
NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.
Media Articles Related to Stromectol (Ivermectin)
Once-Daily Ivermectin Is a Safe Rosacea Treatment
Source: MedicineNet Rosacea Specialty [2015.04.02]
Title: Once-Daily Ivermectin Is a Safe Rosacea Treatment
Category: Health News
Created: 4/2/2015 12:00:00 AM
Last Editorial Review: 4/2/2015 12:00:00 AM
Published Studies Related to Stromectol (Ivermectin)
Efficacy and safety of single and double doses of ivermectin versus 7-day high dose albendazole for chronic strongyloidiasis. [2011.05.10]
BACKGROUND: Strongyloidiasis, caused by an intestinal helminth Strongyloides stercoralis, is common throughout the tropics. It remains an important health problem due to autoinfection, which may result in hyperinfection and disseminated infection in immunosuppressed patients, especially patients receiving chemotherapy or corticosteroid treatment...
A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda. [2011.04]
Integrated chemotherapy of neglected tropical diseases (NTD) through mass drug administration given as a single dose would increase treatment coverage and cost-effectiveness...
Ivermectin and milbemycin oxime in experimental adult heartworm (Dirofilaria immitis) infection of dogs. [2011.01]
BACKGROUND: The US Food and Drug Administration reports an increase in the frequency of reports of lack of effectiveness claims for heartworm (HW) prevention products.
Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. [2010.12.15]
BACKGROUND: Single-dose albendazole and mebendazole show limited efficacy in the treatment of trichuriasis. The combination of albendazole with ivermectin improves efficacy, but a mebendazole-ivermectin combination has not been previously investigated... CONCLUSIONS: Addition of ivermectin improves the therapeutic outcomes of both albendazole and mebendazole against T. trichiura and may be considered for use in soil-transmitted helminth control programs and individual patient management. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN08336605.
Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels. [2010.12.01]
BACKGROUND: Annual mass treatment with albendazole and ivermectin is the mainstay of current strategies to interrupt transmission of Wuchereria bancrofti in Africa. More-effective microfilarial suppression could potentially reduce the time necessary to interrupt transmission, easing the economic burden of mass treatment programs in countries with limited resources... CONCLUSIONS: These findings suggest that increasing the dosage and frequency of albendazole-ivermectin treatment enhances suppression of microfilariae but that this effect may not be attributable to improved adulticidal activity.
Clinical Trials Related to Stromectol (Ivermectin)
Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission [Recruiting]
The purpose of this study is to determine the safety and impact of ivermectin, administered
as single or repeated dose, in combination with artemether-lumefantrine in reducing the
proportion of mosquitoes that survive and become infected after feeding on a blood meal from
a malaria-infected individual.
Ivermectin Versus Albendazole for Chronic Strongyloidiasis [Recruiting]
A prospective controlled trial to compare the efficacy and safety of 7-day albendazole,
single dose ivermectin, and 2-single dose ivermectin in 72 patients with chronic
strongyloidiasis will be conducted at Siriraj Hospital, Bangkok, Thailand.
Study Comparing Moxidectin and Ivermectin in Subjects With Onchocerca Volvulus Infection [Recruiting]
This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and
ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes
river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1
ratio) to receive one orally-administered dose of either moxidectin or ivermectin.
Development of Ivermectin for Alcohol Use Disorders [Not yet recruiting]
Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis [Not yet recruiting]
The purpose of this study is to determine whether 0. 5% ivermectin cream is effective in the
treatment of demodicidosis (including papulopustular rosacea)
Reports of Suspected Stromectol (Ivermectin) Side Effects
Conjunctival Haemorrhage (26),
Urinary Incontinence (11),
Gait Disturbance (11),
Coma (9), more >>
Page last updated: 2015-04-02